Phase 3 Lung Cancer Trial, Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Adults aged 18 years or older.
- People whose general health and ability to carry out daily activities falls within an acceptable range, as measured by a standard oncology scale called ECOG performance status 0–2 (confirm with trial site).
- People with a confirmed diagnosis of non-small cell lung cancer, proven through laboratory testing of tissue samples.
- People whose lung cancer has been classified as Stage 3 using a specific international lung cancer staging system (the IASLC 8th edition guidelines).
- People whose planned treatment includes radiotherapy aimed at curing the cancer (either 60 Gy in 30 sessions or 55 Gy in 20 sessions), with or without chemotherapy given at the same time, and with or without follow-up immune therapy (PD1/PD-L1 inhibitors).
- People who have had a whole-body PET scan (a type of imaging scan) within 8 weeks before registering for the trial.
- People who have had breathing/lung function tests within 8 weeks before registering for the trial.
- People who are willing to provide written consent to participate.
- People who are willing to follow the study procedures and attend all required visits.
- People who are able to be followed up for at least 12 months and up to 3 years.
Additional criteria checked after initial consent:
- A quality of life questionnaire score must reach a minimum threshold that represents a meaningful difference (a specific lung cancer quality of life score of 5 or more).
- The radiation treatment plan must show that at least 16% of the lung tissue (not including the tumour itself) will receive more than 20 Gy of radiation — this is related to the level of risk of a particular lung complication called pneumonitis (confirm with trial site).
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People with serious other health conditions that could make curative radiotherapy unsafe.
- People who are unable to attend the full course of radiotherapy or all follow-up visits.
- People who have ever been diagnosed with interstitial lung disease (a group of conditions affecting lung tissue).
- People who have had a lung cancer diagnosis at any point in the past 5 years.
- People who have previously received radiotherapy to the chest area at any time.
- People who have had surgery for this current lung cancer within the past year.
- People who have already received chemotherapy for this current lung cancer.
- People who are pregnant or currently breastfeeding.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Paul Keall, PhD, University of Sydney
Phone: +61413681368
Australian sites
+61 2 8738 5180
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Patients receiving healthy lung sparing treatment (interventional arm) have better quality of life than patients receiving standard treatment (control arm).
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.